Previous Close | 127.39 |
Open | 131.66 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 131.50 - 131.66 |
52 Week Range | 105.26 - 143.90 |
Volume | |
Avg. Volume | 2,816 |
Market Cap | 205.234B |
Beta (5Y Monthly) | 0.12 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.72 |
Earnings Date | N/A |
Forward Dividend & Yield | 2.84 (2.23%) |
Ex-Dividend Date | Aug 11, 2022 |
1y Target Est | N/A |
Immunovant (IMVT) remains focused on developing its lead pipeline candidate, batoclimab for treating several types of autoimmune diseases. The lack of other pipeline candidates remains a concern.
AstraZeneca said on Monday its cancer drug, Enhertu, developed with Japan's Daiichi Sankyo delayed the progression of a form of advanced breast cancer in previously treated patients, boosting prospects of more regulatory approvals. Enhertu met the main goal of a late-stage study testing the drug against a treatment pre-determined by physicians in people with HER2-positive metastatic breast cancer, the company said. The HER2 protein contributes to the growth and spread of breast cancer.
WILMINGTON, Del., August 12, 2022--AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by a Food and Drug Administration (FDA)-approved test, and who have received a prior systemic therapy.